Cross-Sector entity
Of the tracked stories, 2 of 2 also mention Acadia Pharmaceuticals, the most common co-covered peer. earnings accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. The tracked stories average 2 original sources each.
2 verified stories tracked
Last mentioned: Feb 27, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 2 of 2 also mention Acadia Pharmaceuticals, the most common co-covered peer. earnings accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. The tracked stories average 2 original sources each. Mark C. Schneyer appears in 2 tracked Cross-Sector stories from February 27, 2026.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Mark C. Schneyer. Shared-story counts are live from our verified record — not editorial picks.
Q4 Earnings Call
ACADIA reports strong year-end results and 2026 guidance.
Daybue Stix Launch
Launch of the granule formulation to enhance patient compliance.
Daybue Approval
FDA approves Daybue as the first treatment for Rett syndrome.
Nuplazid Approval
FDA approves Nuplazid for Parkinson's disease psychosis.
ACADIA Pharmaceuticals and Alkami Technology reported Q4 results that highlight divergent paths for mid-cap growth entities. While ACADIA focuses on the commercial scaling of its rare disease portfolio, Alkami is battling a significant stock correction despite beating revenue expectations.
ACADIA Pharmaceuticals delivered a strong Q4 performance, underscored by the rapid adoption of Daybue and the resilience of its Parkinson’s franchise. The results highlight a successful transition into a diversified commercial-stage biotech with a clear path to sustained profitability.
